GROWTH-INHIBITION OF A COLONIC ADENOCARCINOMA CELL-LINE (HT29) BY T-CELLS SPECIFIC FOR MUTANT P21 RAS

被引:14
作者
GEDDEDAHL, T
NILSEN, E
THORSBY, E
GAUDERNACK, G
机构
[1] UNIV OSLO,N-0027 OSLO,NORWAY
[2] NATL HOSP NORWAY,INST PATHOL,IMMUNOHISTOCHEM & IMMUNOPATHOL LAB,N-0027 OSLO,NORWAY
关键词
RAS; ONCOGENE; T CELLS; IMMUNOTHERAPY;
D O I
10.1007/BF01526208
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mutations at codons 12, 13 or 61 of the ras proto-oncogenes are found in adenocarcinomas of the colon and rectum. Mutated ras encode tumor-specific proteins, and can elicit CD4(+) HLA-class-II-restricted T cell responses both in mouse and man. The function of such T cells is, however, unclear. In a model system, we investigated whether HLA-class-II restricted CD4(+) T cells, specific for a particular peptide derived from mutant p21 ras (Gln(61) -> Leu), might inhibit the growth of a colonic cancer cell line, when it was cultured in the presence of the corresponding peptide. We found in this case that the growth of the colonic adenocarcinoma cell line HT29, when also induced to express HLA class II molecules by interferon gamma treatment, was inhibited. The inhibition was peptide-specific and required the presence of HLA-DQ8 molecules on the target cell. However, HLA-DQ8-expressing HT29 cells functioned poorly as antigen-presenting cells and could only induce a weak proliferative T cell response in the presence of interleukin-2. The results suggest that colonic cancer cells expressing peptides derived from mutant p21 ras protein in a complex with HLA class II molecules may be a target for tumor-specific T cells. The results also indicate, however, that an initiation of the immune response will require ''professional'' antigen-presenting cells.
引用
收藏
页码:127 / 134
页数:8
相关论文
共 41 条
[11]   A HIGHLY SENSITIVE CELL-LINE, WEHI-164 CLONE 13, FOR MEASURING CYTOTOXIC FACTOR TUMOR-NECROSIS-FACTOR FROM HUMAN-MONOCYTES [J].
ESPEVIK, T ;
NISSENMEYER, J .
JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 95 (01) :99-105
[12]  
FOSSUM B, 1993, IN PRESS EUR J IMMUN
[13]  
FOSSUM B, 1993, IN PRESS INT J CANCE
[14]   INTERLEUKIN-10 PRODUCTION BY HUMAN CARCINOMA CELL-LINES AND ITS RELATIONSHIP TO INTERLEUKIN-6 EXPRESSION [J].
GASTL, GA ;
ABRAMS, JS ;
NANUS, DM ;
OOSTERKAMP, R ;
SILVER, J ;
LIU, F ;
CHEN, M ;
ALBINO, AP ;
BANDER, NH .
INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (01) :96-101
[15]  
GAUDERNACK G, 1989, J IMMUNOGENET, V16, P169
[16]   T-CELL RESPONSES AGAINST PRODUCTS OF ONCOGENES - GENERATION AND CHARACTERIZATION OF HUMAN T-CELL CLONES SPECIFIC FOR P21 RAS-DERIVED SYNTHETIC PEPTIDES [J].
GEDDEDAHL, T ;
ERIKSEN, JA ;
THORSBY, E ;
GAUDERNACK, G .
HUMAN IMMUNOLOGY, 1992, 33 (04) :266-274
[17]   MEMORY T-CELLS OF A PATIENT WITH FOLLICULAR THYROID-CARCINOMA RECOGNIZE PEPTIDES DERIVED FROM MUTATED P21 RAS (GLN-]LEU61) [J].
GEDDEDAHL, T ;
SPURKLAND, A ;
ERIKSEN, JA ;
THORSBY, E ;
GAUDERNACK, G .
INTERNATIONAL IMMUNOLOGY, 1992, 4 (11) :1331-1337
[18]   THERAPY OF DISSEMINATED MURINE LEUKEMIA WITH CYCLOPHOSPHAMIDE AND IMMUNE LYT-1+,2- T-CELLS - TUMOR-ERADICATION DOES NOT REQUIRE PARTICIPATION OF CYTO-TOXIC T-CELLS [J].
GREENBERG, PD ;
KERN, DE ;
CHEEVER, MA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1985, 161 (05) :1122-1134
[19]  
HAMER PJ, 1991, ONCOGENE, V6, P1609
[20]   INTRACELLULAR EVENTS ASSOCIATED WITH INHIBITION OF B-CELL ACTIVATION BY MONOCLONAL-ANTIBODIES TO HLA CLASS-II ANTIGENS [J].
HOLTE, H ;
BLOMHOFF, HK ;
BEISKE, K ;
FUNDERUD, S ;
TORJESEN, P ;
GAUDERNACK, G ;
STOKKE, T ;
SMELAND, EB .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1989, 19 (07) :1221-1225